|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,901 JPY | +1.32% |
|
-2.32% | -16.32% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Apr. 01 | BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug | MT |
(Reuters) - Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug.
The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Stephen Coates)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 5,901 JPY | +1.32% | -2.32% | 10.8B | ||
| 190.5 USD | -0.85% | -6.46% | 27.69B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -16.32% | 10.8B | |
| +27.97% | 672B | |
| +23.36% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +1.91% | 211B | |
| -0.68% | 203B | |
| -10.35% | 194B | |
| -11.81% | 144B |
EISAI CO., LTD. 
